16 4
Table 10.2
(continued)
In vivo studiesDisease model
Mode of administration
Animal model
Outcome
References
Clinical trials
Disease condition
Cell type used
No. of patients enrolled
Route of administration
No. of cells administered
Outcome
References
Multiple sclerosis
ERCs
4
Intravenous and intrathecal
16–30 × 10
6
No immunological reactions or adverse side effect on 1 year follow up
[^58
]
DMD
ERCs
1
Intramuscular
116 × 10
6
↑ Muscle strength and
↓ respiratory
infection on 3 year follow-up
[^59
]
Ischemic cardiomyopathy
Allogeneic CD34 cells + ERCs
1
Intravenous
15 × 10
6
No mass formation, inflammation. EF increased from 30% to 40%,
↓ basic
natriuretic peptide values
[^60
]
K.G. Aghila Rani and T. Madan